Publications en collaboration avec des chercheurs de Hospital Clinic Barcelona (18)

2024

  1. Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis

    Reumatologia Clinica, Vol. 20, Núm. 8, pp. 423-439

2019

  1. A composite indicator to assess the quality of care in the management of patients with rheumatoid arthritis in outpatient rheumatology clinics

    Reumatologia Clinica, Vol. 15, Núm. 3, pp. 156-164

  2. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept

    PLoS ONE, Vol. 14, Núm. 2

  3. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial

    Arthritis and Rheumatology, Vol. 71, Núm. 10, pp. 1616-1625

2018

  1. Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis

    PLoS ONE, Vol. 13, Núm. 5

2017

  1. REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients

    Heliyon, Vol. 3, Núm. 11

  2. Recommendations for the evaluation and management of patients with rheumatic autoimmune and inflammatory diseases during the reproductive age, pregnancy, postpartum and breastfeeding

    Reumatologia Clinica, Vol. 13, Núm. 5, pp. 264-281

2016

  1. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

    Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140

2015

  1. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide

    Reumatologia Clinica, Vol. 11, Núm. 5, pp. 279-294

  2. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors

    Pharmacogenomics, Vol. 16, Núm. 4, pp. 333-345

  3. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study

    Arthritis Research and Therapy, Vol. 17, Núm. 1

2014

  1. Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study

    Arthritis Research and Therapy, Vol. 16, Núm. 1

2012

  1. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population

    Scandinavian Journal of Rheumatology, Vol. 41, Núm. 1, pp. 10-14

2010

  1. Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms

    Rheumatology, Vol. 49, Núm. 3, pp. 458-466

2009

  1. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility

    Arthritis Research and Therapy, Vol. 11, Núm. 2

2008

  1. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis

    Arthritis and Rheumatism, Vol. 58, Núm. 5, pp. 1264-1274

2006

  1. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

    Arthritis Research and Therapy, Vol. 8, Núm. 1

2004

  1. Intolerancia a la hidroxicloroquina comercializada en España (Dolquine®) en pacientes con patología autoinmune

    Revista Clinica Espanola, Vol. 204, Núm. 11, pp. 588-591